Top Markets
#1 Palladium Network Palladium Network +27.90%
#2 Ankr Network Ankr Network +26.55%
#3 BankrCoin BankrCoin +15.90%
#4 Status Status +15.24%
#5 Siren Siren +8.82%
#6 WAX WAX +6.92%
#7 Wrapped Aave Ethereum WETH Wrapped Aave Ethereum WETH +6.84%
#8 Wiki Cat Wiki Cat +6.64%
#9 would would +6.14%
#10 Asteroid Shiba Asteroid Shiba +5.16%
Coin of the day
Palladium Network Palladium Network
Settings
Language
ENGLISH
Currency
USD
Theme
Voyager Therapeutics, Inc. Voyager Therapeutics, Inc.

Voyager Therapeutics, Inc.

VYGR
Rank in Stocks #18068
Voyager Therapeutics, Inc. operates as a gene therapy company, concentrating... Voyager Therapeutics, Inc. operates as a gene therapy company, concentrating its efforts on developing innovative treatments and pioneering advanced platform technologies. Its leading clinical asset, VY-AADC, is presently undergoing an open-label Phase 1 clinical trial for the management of Parkinson's disease. The company's preclinical portfolio is extensive, featuring VY-SOD102 for amyotrophic lateral sclerosis (ALS), VY-HTT01 for Huntington's disease, and VY-FXN01 for Friedreich's ataxia. Additionally, Voyager is pursuing a Tau program aimed at various tauopathies, including Alzheimer's disease, progressive supranuclear palsy, and frontotemporal dementia, alongside initiatives for spinal muscular atrophy. To advance its gene therapy product pipeline, the company has forged strategic collaboration and licensing agreements with key industry players such as Neurocrine Biosciences, Inc., Pfizer Inc., and Novartis Pharma, A.G. These partnerships cover the research, development, and commercialization of adeno-associated virus-based gene therapy products. Voyager Therapeutics, Inc. was founded in 2013 and maintains its corporate headquarters in Cambridge, Massachusetts.
Share Price
$3.54
Last synced: 2026-09-02
Market Cap
$213.59M
Change (1 day)
3.06%
Change (1 year)
-3.94%
Country
US
Trade Voyager Therapeutics, Inc. (VYGR)

Category

Healthcare
Revenue for Voyager Therapeutics, Inc. (VYGR)
Revenue in Sep 2026 TTM: 0
According to Voyager Therapeutics, Inc. latest financial reports the company's current revenue (TTM) is 0. In 2026 the company made a revenue of 0 equal to the revenue in the year 2026 that was 0. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Voyager Therapeutics, Inc. from 2026 to 2026
Revenue at the end of each year
Year Revenue Change
Not enough data for the provided dates.
Revenue for similar companies or competitors
Company Revenue Revenue Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $2.23B -
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $15.74B -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH